focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,783.50
Bid: 1,780.00
Ask: 1,780.50
Change: -29.00 (-1.60%)
Spread: 0.50 (0.028%)
Open: 1,792.50
High: 1,802.00
Low: 1,775.50
Prev. Close: 1,812.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET CLOSE: FTSE 100 underwhelms as stocks jump after US CPI

Tue, 14th Nov 2023 17:04

(Alliance News) - European equities jumped in the wake of a cooler-than-expected US inflation reading, which took some sting out of a recent hawkish reassessment of the Federal Reserve interest rate outlook.

A hold by the US central bank next month is now completely priced in. According to the CME FedWatch Tool, there was a 15% chance of a hike a day ago, as investors digested hawkish comments from Fed Chair Jerome Powell from last week.

The FTSE 100 index rose by 14.64 points, 0.2%, at 7,440.47. It represents a solid gain, though massively underperforming peers.

The FTSE 250 shot up 622.48 points, 3.5%, at 18,536.13, and the AIM All-Share rose 8.85 points, 1.3%, at 709.72.

The Cboe UK 100 rose 0.3% at 743.54, the Cboe UK 250 jumped 3.8% at 16,064.08, and the Cboe Small Companies surged 1.8% at 13,192.44.

In European equities on Tuesday, the CAC 40 in Paris surged 1.4%, while the DAX 40 in Frankfurt shot up 1.8%.

According to the Bureau of Labor Statistics, the consumer price index rose by 3.2% in October from a year before, slowing from a 3.7% increase in September. The inflation rate had been expected to cool only to 3.3%, according to FXStreet-cited market consensus.

The rate of inflation is now closer to the Fed's 2% target.

The core annual inflation rate eased to 4.0% in October from 4.1% in September, a pace it had been expected to maintain last month.

The Fed earlier in November left the federal funds rate range unmoved at 5.25% to 5.50%, a 22-year-high, and where it has been since July.

But hiking expectations picked up slightly after Chair Jerome Powell struck a hawkish tone last week.

Powell said Thursday that the Fed was prepared to hike again if needed.

The Fed chair's words gave the dollar some support towards the back end of last week, but the greenback was on the back foot on Tuesday, even prior to the inflation data.

Sterling was quoted at USD1.2475 late Tuesday afternoon, higher than USD1.2264 at the London equities close on Monday. The pound was trading around a two-month-high.

The euro traded at USD1.0855 on Tuesday afternoon, up from USD1.0696 at the London equities close on Monday. Against the yen, the dollar was quoted at JPY150.85, down versus JPY151.59.

Gold was quoted at USD1,964.57 an ounce late Tuesday, up from USD1,945.38 on Monday. The precious metal has an inverse relationship with the dollar.

In New York, the Dow Jones Industrial Average was up 1.7%, the S&P 500 surged 2.1% and the Nasdaq Composite jumped 2.3%, with tech shares benefitting from the cooler US inflation reading.

Interest rate sensitive stocks in London also shone. Warehouse investor Segro and housebuilder Taylor Wimpey added 6.4% and 8.1% as the property excelled in the wake of the US data, as rate worries eased.

It was not only in foreign currency and equity markets where moves were dramatic post-US data. The yield on the US 10-year Treasury eased markedly to as low as 4.43% following the data, from a high of 4.70% on Monday.

The stronger sterling meant the FTSE 100 was unable to rise as strongly as European peers. London's blue-chip index is stacked with international earners.

Index heavyweights such as GSK, Shell and Unilever fell 1.7%, 1.4% and 0.9%.

A hefty 5.5% fall for Vodafone also kept a lid on the FTSE 100. The Newbury, Berkshire-based telecommunications provider said pretax profit in the six months to September 30 dived to EUR550 million from EUR1.69 billion a year prior. Revenue fell 4.3% to EUR21.94 billion from EUR22.93 billion.

It swung to a net loss of EUR155 million, from profit of EUR1.20 billion.

At the other end of the FTSE 100, DCC surged 12%. It said revenue and profit both fell in the latest half year but declared an increased dividend.

The Dublin-based sales, marketing and support services firm said pretax profit for the six months that ended on September 30 was GBP129.7 million, down from GBP312.3 million the previous year.

Revenue fell 11% to GBP9.62 billion from GBP10.84 billion. This was mainly due to lower average commodity prices, which caused DCC Energy revenue to decrease 9.7% to GBP2.3 billion.

DCC nonetheless declared an interim dividend of 63.04 pence per share, up 5.0% from 60.04 pence the year before.

Elementis rose 5.2%. It set out a lofty margin target and said it plans "above market revenue growth by 2026".

The speciality chemicals firm, hosting a capital markets day in the wake of receiving calls from some shareholders for an immediate sale of the company, also said it is eyeing cost cuts.

London-based Elementis is looking for an adjusted operating profit margin above 19% as part of its 2026 financial targets. It achieved an adjusted operating profit margin of 13.6% in 2022, rising from 12.4% in 2021.

"The 19% target operating margin will be achieved through our growth and efficiency programmes based on current market conditions, whilst a modest recovery in the demand environment could see the margin rise above this level," Elementis said.

It is also targeting delivering "USD90 million of above market revenue growth by 2026".

The capital markets day comes after Elementis has faced shareholder scrutiny recently.

In September, Franklin Mutual Advisors, an investment advisory firm parented by Franklin Templeton, published an open letter requesting that the Elementis board "initiate an immediate sale of the company".

The targets announced by Elementis on Tuesday were not enough to win over Franklin.

"The proposed targets are based on multiple assumptions several years into the future. The current management has been in charge for nearly eight years and consistently disappointed shareholders with value destruction and missed targets. We continue to believe that the company should start a formal sales process to maximize shareholder value," Franklin Mutual Series Senior Vice President-Portfolio Manager Steve Raineri said.

AIM-listed Horizonte Minerals tumbled 48%. It said it will scale back construction activities at its Araguaia nickel asset in Brazil to manage its resources and funds.

Horizonte said it will be advancing only critical workstreams, as it attempts to save cash as it tries to secure more funding.

The Araguaia project had total liquidity sources of USD169 million at November 10, which it explained "should provide sufficient working capital to around mid-December 2023 unless there are positive outcomes from conversations with suppliers, other cash preserving measures, or other financing solutions".

It added that financing discussions with shareholders and lenders continue.

Brent oil was trading at USD83.42 a barrel at the time of the European equities, rising from USD82.39 a day prior.

Wednesday's economic calendar has China retail sales data and a Japanese gross domestic product reading overnight. There is UK inflation data at 0700 GMT, eurozone industrial production at 1000 GMT and a US producer price index at 1330 GMT.

The local corporate calendar has half-year results from utility firm SSE and pub company Fuller, Smith & Turner.

By Eric Cunha, Alliance News news editor

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
6 Feb 2024 07:47

LONDON BRIEFING: BP promises buyback despite drop in profit

(Alliance News) - Stocks in London are called to open higher, ahead of a slew of construction purchasing managers' index readings from the eurozone, the UK and Germany.

Read more
6 Feb 2024 07:23

GSK reports positive myeloma trial results, progresses vaccine applications

(Sharecast News) - GSK reported progress in its trial of a myeloma treatment on Tuesday, as well as regulatory progress around its shingles vaccine in China and its RSV vaccine in the United States.

Read more
1 Feb 2024 09:27

TOP NEWS: GSK maintains "vigorous" defence after settling Zantac case

(Alliance News) - GSK PLC on Thursday insisted upon its scientific integrity, after reaching another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
1 Feb 2024 09:11

GSK settles Zantac case in California without admitting liability

(Sharecast News) - GSK announced on Thursday that it had reached a confidential settlement to effectively resolve the legal case over Zantac filed in a California state court.

Read more
1 Feb 2024 09:03

LONDON BROKER RATINGS: Barclays cuts Next; JPMorgan raises easyJet

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning:

Read more
1 Feb 2024 07:42

LONDON BRIEFING: Shell profit falls; announces USD3.5 billion buyback

(Alliance News) - Stocks in London are set to follow New York into the red, after the US Federal Reserve quashed hopes of a March cut to interest rates and ahead of the Bank of England interest rate decision.

Read more
31 Jan 2024 17:05

LONDON MARKET CLOSE: Stocks mixed hours before expected US Fed hold

(Alliance News) - Stock prices in London closed mixed on Wednesday in a trade-thinned day ahead of the US Federal Reserve interest rate decision this evening.

Read more
31 Jan 2024 15:49

London close: Stocks mixed ahead of US Fed, BoE decisions

(Sharecast News) - London's financial markets finished with mixed performance on Wednesday, with investors closing their wallets ahead of rate announcements from both the US Federal Reserve and the Bank of England.

Read more
31 Jan 2024 12:05

LONDON MARKET MIDDAY: FTSE 100 flat ahead of Federal Reserve decision

(Alliance News) - The FTSE 100 in London was flat heading into Wednesday afternoon, as the US Federal Reserve's latest interest rate decision edges closer, keeping equity market enthusiasm to a minimum.

Read more
31 Jan 2024 09:13

TOP NEWS: GSK profit up on Arexvy boost in 2023 but total payout down

(Alliance News) - GSK PLC reported an increase in profit and revenue for 2023 as revenue for HIV medicine had stable growth, amid optimism in the company's outlook.

Read more
31 Jan 2024 08:55

LONDON MARKET OPEN: Stocks lack direction ahead of Fed, BoE

(Alliance News) - Stock prices in London lacked direction at the open on Wednesday, as investors nervously look ahead to interest rate decisions from the US Federal Reserve and Bank of England.

Read more
31 Jan 2024 07:46

LONDON BRIEFING: Stocks called up; GSK revenue and profit up

(Alliance News) - Stocks in London are called to open higher, as markets share of nerves around the next set of interest rate decisions.

Read more
29 Jan 2024 08:51

GSK seeks expanded use of RSV vaccine in EU, wins approval for Omjjara

(Alliance News) - GSK PLC on Monday celebrated regulatory progress for two of its products in the EU.

Read more
29 Jan 2024 07:43

LONDON BRIEFING: Superdry looks at saving costs; Ferrexpo loses case

(Alliance News) - Stocks in London are expected to start the week on a cautious note, as investors nervously look ahead to two key interest rate decisions.

Read more
29 Jan 2024 07:07

GSK gets EU approval to sell blood cancer treatment Omijara

(Sharecast News) - Biopharma giant GSK has been given the green light by European regulators to sell Omjjara, its treatment for patients with a rare type of blood cancer.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.